The National Cancer Institute (NCI) is investigating ivermectin’s potential anticancer properties through preclinical research, which is distinct from commercial claims and the controversial Hulscher et al. 2026 study. NCI’s findings are not clinical endorsements, highlighting the need for caution regarding off-label uses and overlapping commercial interests in cancer treatment discussions.
